切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (04) : 246 -249. doi: 10.3877/cma.j.issn.2095-3232.2015.04.013

所属专题: 文献

基础研究

siRNA沉默ENAH基因对肝癌细胞生长的抑制作用
黄群爱1, 胡昆鹏2,(), 刘波2, 姚志成2, 熊志勇3   
  1. 1. 510630 广州,中山大学附属第三医院甲状腺乳腺外科
    2. 510530 广州,中山大学附属第三医院岭南医院普通外科
    3. 510630 广州,中山大学附属第三医院肝胆外科
  • 收稿日期:2015-06-12 出版日期:2015-08-10
  • 通信作者: 胡昆鹏
  • 基金资助:
    教育部博士点基金新教师类(20110171120089)

Inhibition of ENAH gene silenced by siRNA on growth of liver cancer cell

Qunai Huang1, Kunpeng Hu2,(), Bo Liu2, Zhicheng Yao2, Zhiyong Xiong3   

  1. 1. Department of Thyroid Breast Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    2. Department of General Surgery, Lingnan Hospital, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510530, China
    3. Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2015-06-12 Published:2015-08-10
  • Corresponding author: Kunpeng Hu
  • About author:
    Corresponding author: Hu Kunpeng, Email:
引用本文:

黄群爱, 胡昆鹏, 刘波, 姚志成, 熊志勇. siRNA沉默ENAH基因对肝癌细胞生长的抑制作用[J/OL]. 中华肝脏外科手术学电子杂志, 2015, 04(04): 246-249.

Qunai Huang, Kunpeng Hu, Bo Liu, Zhicheng Yao, Zhiyong Xiong. Inhibition of ENAH gene silenced by siRNA on growth of liver cancer cell[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(04): 246-249.

目的

探讨siRNA沉默ENAH基因对肝癌细胞生长的抑制作用。

方法

采用脂质体Lipofectamine 2000将ENAH-siRNA及control-siRNA转染至人肝癌细胞HCCLM3,分别设为ENAH-siRNA组和control-siRNA组。采用Western blot检测ENAH蛋白表达,采用裸鼠成瘤实验观察肝癌细胞致瘤能力。记录肿瘤体积,绘制生长曲线,进行生存分析。两组实验数据比较采用t检验,生存分析采用Kaplan-Meier法和Log-rank检验。

结果

ENAH-siRNA组细胞ENAH蛋白表达明显弱于control-siRNA组。ENAH-siRNA组裸鼠接种后实体肿瘤形成时间为(24±3)d,明显长于control-siRNA组的(8±2)d(t=12.55,P<0.05)。ENAH-siRNA组裸鼠中位生存时间为64(48~81)d,control-siRNA组为34(21~48)d,两组总体生存率比较差异有统计学意义(χ2=14.33,P<0.05)。

结论

siRNA沉默ENAH基因可明显减弱肝癌细胞的致瘤能力,抑制肿瘤生长。

Objective

To investigate the inhibition of ENAH gene silenced by siRNA on the growth of liver cancer cell.

Methods

ENAH-siRNA and control-siRNA were transfected to human liver cancer cell HCCLM3 using liposome Lipofectamine 2000 and ENAH-siRNA group and control-siRNA group were established. The expression of ENAH protein was detected by Western blot. Tumorigenic ability of the liver cancer cell was observed through nude mice tumorigenicity assay. Tumor volume was recorded, growth curve was drawn and survival analysis was conducted. The experimental data of two groups were compared using t test, and the survival analysis was conducted using Kaplan-Meier method and Log-rank test.

Results

The expression of ENAH protein in ENAH-siRNA group was significantly less than that in control-siRNA group. The formation time of solid tumor after inoculation in nude mice in ENAH-siRNA group was (24±3) d, which was significantly longer than (8±2) d in control-siRNA group (t=12.55, P<0.05). The median survival time of the nude mice was 64 (48~81) d in ENAH-siRNA group and was 34 (21~48) d in control-siRNA group. There was significant difference in the overall survival rate between two groups (χ2=14.33, P<0.05).

Conclusion

ENAH gene silenced by siRNA may obviously weaken the tumorigenic ability of liver cancer cell and inhibit the growth of tumor.

图1 Western blot检测ENAH-siRNA组和control-siRNA组细胞ENAH蛋白表达
[1]
郭宇,陈规划.肝细胞肝癌合并肝静脉、下腔静脉及右心房癌栓的诊断与治疗[J/CD].中华肝脏外科手术学电子杂志,2013, 2(1):53-55.
[2]
安玉玲,张婷婷,蔡常洁.西罗莫司用于治疗肝癌肝移植术后肿瘤复发患者的疗效分析[J].器官移植,2011, 2(2):73-76.
[3]
范上达,邱宗祥,潘冬平.肝癌的综合治疗[J].中华消化外科杂志,2011, 10(4):241-246.
[4]
Loya CM, Mcneill EM, Bao H, et al. miR-8 controls synapse structure by repression of the actin regulator enabled[J]. Development, 2014, 141(9):1864-1874.
[5]
Winkelman JD, Bilancia CG, Peifer M, et al. Ena/VASP Enabled is a highly processive actin polymerase tailored to self-assemble parallel-bundled F-actin networks with Fascin[J]. Proc Natl Acad Sci U S A, 2014, 111(11):4121-4126.
[6]
Agarwal S, Gertler FB, Balsamo M, et al. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer[J]. Breast Cancer Res, 2012, 14(5):R124.
[7]
Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148(1/2):349-361.
[8]
Bessède E, Staedel C, Acuña Amador LA, et al. Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes[J]. Oncogene, 2014, 33(32):4123-4131.
[9]
Chen XJ, Squarr AJ, Stephan R, et al. Ena/VASP proteins cooperate with the WAVE complex to regulate the actin cytoskeleton[J]. Dev Cell, 2014, 30(5):569-584.
[10]
Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development[J]. Development, 2012, 139(19):3471-3486.
[11]
Gurzu S, Turdean S, Kovecsi A, et al. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: an update[J]. World J Clin Cases, 2015, 3(5):393-404.
[12]
Jain P, Spaeder MC, Donofrio MT, et al. Detection of alpha II-spectrin breakdown products in the serum of neonates with congenital heart disease[J]. Pediatr Crit Care Med, 2014, 15(3):229-235.
[13]
Huang T, Chen Z, Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells[J]. Oncol Rep, 2013, 29(1):117-124.
[14]
Chen Y, Yao F, Chen S, et al. Endogenous BNP attenuates cardiomyocyte hypertrophy induced by Ang II via p38 MAPK/Smad signaling[J]. Pharmazie, 2014, 69(11):833-837.
[15]
Emami H, Vucic E, Subramanian S, et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial[J]. Atherosclerosis, 2015, 240(2):490-496.
[16]
Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer[J]. Cancer Res, 2012, 72(19):4883-4889.
[17]
Hu K, Wang J, Yao Z, et al. Expression of cytoskeleton regulatory protein Mena in human hepatocellular carcinoma and its prognostic significance[J]. Med Oncol, 2014, 31(5):939.
[1] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[3] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[4] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[5] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[6] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[7] 林小勇, 张兰霞, 曾庆劲, 贺需旗, 谭雷, 郭光辉, 龙颖琳, 李凯, 吴宇轩. 负压抽吸活检针在肝困难病灶活检中的初步应用研究[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 694-698.
[8] 雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
[9] 欧阳佳裕, 李刚, 贺露瑶, 罗娜. 双层探测器光谱CT在早期原发性肝癌中的诊断价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 557-561.
[10] 陈志坚, 俞建达, 池小斌, 吕立志, 陈永标. 三维可视化技术在腹腔镜肝巨大肿瘤切除中的应用价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 302-307.
[11] 黄俊豪, 陈宗杰, 胡添松. 血小板相关参数对肝内胆管细胞癌根治性切除患者预后预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 308-312.
[12] 马欢欢, 马晨辉, 邓小博, 王博方, 何普毅, 王云鹏, 许博, 俞荣, 王娜, 陈昊. 肝癌实体瘤治疗疗效评价系统的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 377-383.
[13] 王凯飞, 牟怡平, 李晓辉, 王瑞涛, 侯惠莲, 张月浪. 原发性肝平滑肌肉瘤临床病理特征及疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 357-362.
[14] 张婵, 吕瑶, 张小燕, 张鸣青. 不同时机局部神经阻滞在开腹肝切除中的镇痛效果比较[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 189-194.
[15] 沈佳佳, 何经雄, 王芳, 江艺, 潘凡, 张小进. ICG荧光引导腹腔镜射频消融在合并严重大结节肝硬化小肝癌患者治疗中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 68-71.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?